1. Pink Sheet
  2. >>Pathways & Standards
  3. >>User Fees

User Fee Renewal Negotiations Beginning This Week

 
• By Derrick Gingery

Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.

Businessman working with calculator and document data - Image
User fee reauthorization negotiations will be virtual rather than in-person. • Source: Shutterstock

Formal negotiations between industry and the US Food and Drug Administration to reauthorize the generic drug and prescription drug user fees will begin this month, with talks for one program opening this week.

Representatives of industry and the agency will use the talks to draft improvements to the PDUFA and GDUFA programs, which...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from User Fees

PDUFA VIII: FDA Pilot Programs, Workforce Challenges Could Shape Renewal Debate

 
• By Sue Sutter

The next iteration of the user fee program could depart from longstanding agency commitments to issue formal guidance given the Trump Administration’s deregulatory philosophy, policy experts said.

Tidmarsh Creates More Instability And Uncertainty For US FDA, Industry

 
• By Sarah Karlin-Smith

The issues surrounding the FDA's Center for Drug Evaluation and Research director are raising new concerns about more career staff attrition, which likely will negatively impact the drug industry.

US FDA User Fee Balances Holding, Thanks In Part To Earlier Staff Cuts

 
• By Derrick Gingery

An agency official said reserve user fee money is expected to continue funding application review and other activities for several more weeks.

GDUFA IV Talks Begin, Embracing Traditional Process

 
• By Derrick Gingery

The introductory meeting did not suggest changes to the expected schedule and operations for renewing the generic drug user fee, said AAM’s Giuseppe Randazzo.

More from Pathways & Standards

Where RWE Studies Stand In India And Bharat Serums’ Plans For The World’s Largest One

 
• By Vibha Ravi

Real-world evidence (RWE) studies in India face challenges like lack of data reliability and uniformity and absence of clear guidelines but firms like Bharat Serums have scored a regulatory win. Pink Sheet examines the RWE landscape and the BSV case study for lessons in beating the odds

Epilepsy Cell Therapy NRTX-1001 Among Trio Of Drugs To Win EMA PRIME Designations

 
• By Neena Brizmohun

NRTX-1001, taladegib and AZD0292 are the latest investigational products to make it onto PRIME, the European Medicines Agency’s priority medicines scheme for drugs for unmet medical needs.

Tidmarsh Creates More Instability And Uncertainty For US FDA, Industry

 
• By Sarah Karlin-Smith

The issues surrounding the FDA's Center for Drug Evaluation and Research director are raising new concerns about more career staff attrition, which likely will negatively impact the drug industry.